Storia in 5 fonti

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are interpretable and RP1 works.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 g fa

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are interpretable and RP1 works.

originale

Timeline cronologica

martedì 28 luglio 2026·medpagetoday.com
FDA Staff Unconvinced Drug for Melanoma Shows Benefit
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
martedì 28 luglio 2026·statnews.com
FDA staff reiterate concerns about Replimune skin cancer treatment
Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Confronto fonti

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Timeline cronologica

FDA Staff Unconvinced Drug for Melanoma Shows Benefit

FDA staff reiterate concerns about Replimune skin cancer treatment

Replimune melanoma drug wins support of FDA panel

FDA Staff Unconvinced Drug for Melanoma Shows Benefit

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)

FDA expert committee votes in favor of Replimune’s melanoma treatment

FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff - Replimune Group (NASDAQ:REPL)

FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

Replimune melanoma drug wins support of FDA panel

Tracking the FDA expert review of Replimune’s melanoma treatment

FDA expert committee votes in favor of Replimune’s melanoma treatment

Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism

Pharmalittle: We're reading about a Novo setback, support for Replimune's melanoma drug, and more

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)